ANKH Knockout HCT 116 Cell Line
Cat.No.:
EDC07825
Species:
Human
Cell Name:
HCT 116
Gene:
ANKH
Gene ID:
56172
Size:
1×10⁶cells
ANKH Knockout HCT116 Cell Line is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performotion Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC07825 |
|---|---|
| Product Name | ANKH Knockout HCT116 Cell Line |
| Species | Human |
| Cell Line | HCT 116 |
| Cellosaurus ID | CVCL_0291 |
| Gene ID | |
| Cell Line Synonyms | HCT-116, HCT.116, HCT_116, HCT116, HCT116wt, HCT-116/P, HCT-116/parental, CoCL2 |
| Gene | ANKH |
| Gene Synonyms | ANK|CCAL2|CMDJ|CPPDD|HANK|MANK|SLC62A1 |
| Summary |
This gene encodes a multipass transmembrane protein that is expressed in joints and other tissues and controls pyrophosphate levels in cultured cells. Progressive ankylosis-mediated control of pyrophosphate levels has been suggested as a possible mechanism regulating tissue calcification and susceptibility to arthritis in higher animals. Mutations in this gene have been associated with autosomal dominant craniometaphyseal dysplasia. [provided by RefSeq, Jul 2008]
|
| Digestion Time | 3 min |
| Associated Diseases | Colorectal Carcinoma |
| Morphology | Adherent |
| Passage Ratio | 1:8~1:10 |
| Complete Culture Medium | mcCoy5A+10% FBS |
| Freezing Medium | 90% FBS/complete culture medium+10% DMSO |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HCT 116 | STR Info (Cell bank) Cell Line: HCT 116 | ||||||
| Allele1 | Allele2 | Allele3 | Allele4 | Allele1 | Allele2 | Allele3 | Allele4 | |
| Amelogenin | X | X | ||||||
| CSF1PO | 7 | 10 | 7 | 9 | 10 | 11 | ||
| D2S1338 | 16 | 16 | ||||||
| D3S1358 | 12 | 17 | 18 | 19 | 12 | 18 | 19 | |
| D5S818 | 10 | 11 | 10 | 11 | ||||
| D7S820 | 11 | 12 | 11 | 12 | ||||
| D8S1179 | 10 | 12 | 14 | 15 | 10 | 12 | 14 | 15 |
| D13S317 | 10 | 12 | 10 | 12 | ||||
| D16S539 | 11 | 13 | 11 | 12 | 13 | 14 | ||
| D18S51 | 16 | 17 | 16 | 17 | ||||
| D19S433 | 12 | 13 | 12 | |||||
| D21S11 | 29 | 30 | 29 | 30 | ||||
| FGA | 18 | 23 | 18 | 23 | ||||
| Penta D | 9 | 13 | 9 | 13 | ||||
| Penta E | 12 | 13 | 14 | 12 | 13 | 14 | ||
| TH01 | 8 | 9 | 8 | 9 | ||||
| TPOX | 8 | 8 | ||||||
| vWA | 17 | 21 | 22 | 23 | 17 | 21 | 22 | 23 |
| D6S1043 | 13 | |||||||
| D12S391 | 17 | 21 | 22 | |||||
| D2S441 | 11 | 12 | ||||||
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying ANKH function, ANKH Knockout HCT 116 Cell Line or ANKH overexpression HCT 116 Cell Line?
The choice depends on whether you are studying ANKH (progressive ankylosis protein homolog)'s role as a pyrophosphate transporter or modeling its functions in skeletal biology and emerging immune applications. The Knockout line is the standard tool for asking whether ANKH is required for these processes — ANKH is a transmembrane protein that mediates inorganic pyrophosphate (PPi) and citrate transport across the plasma membrane, with critical roles in skeletal mineralization (PPi inhibits hydroxyapatite formation); recent studies (Kirsch et al. 2021) have characterized ANKH-mediated ATP and citrate transport as an emerging mechanism in inflammation. Overexpression is useful for studying ANKH gain-of-function effects.
For skeletal and emerging immune biology research, the EDITGENE ANKH Knockout in HCT 116 enables study of ANKH biology. ANKH gain-of-function mutations cause ⭐ craniometaphyseal dysplasia (autosomal dominant) and chondrocalcinosis (familial pseudogout) — these mutations increase ANKH activity. Rescue with wild-type or disease-mutant ANKH enables disease genotype-function studies. The knockout is valuable for studying pyrophosphate biology, skeletal mineralization, chondrocalcinosis disease modeling, and emerging ANKH-mediated immunometabolite transport.
What are the application scenarios for this model?
Primary applications:
• Pyrophosphate transport: extracellular PPi measurement in ANKH-null cells given ANKH's PPi efflux function.
• Craniometaphyseal dysplasia modeling: rescue with patient-derived ANKH mutations (gain-of-function in CMD) for disease genotype-function studies.
• Chondrocalcinosis modeling: rescue with familial pseudogout-causing ANKH mutations.
• Mineralization studies: in heterologous mineralization-relevant contexts, hydroxyapatite formation analysis.
EDITGENE recommends this model for researchers investigating pyrophosphate biology and skeletal mineralization disorders.
Is this ANKH Knockout HCT 116 Cell Line compatible with overexpression rescue experiments?
Yes. ANKH rescue experiments require attention to membrane transporter architecture:
• Construct design: use a codon-modified ANKH sequence with a small intracellular tag (FLAG, HA). ANKH has multiple transmembrane domains — preserve membrane topology.
• CMD/chondrocalcinosis mutation rescue: gain-of-function mutations enable disease genotype-function studies (CMD mutations increase ANKH activity).
• Surface localization validation: confirm plasma membrane ANKH localization before transport assays.
• Functional readout: rescue should restore extracellular PPi efflux measured by enzymatic PPi assays.
HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
download